News

EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Exelixis Inc (EXEL) reports robust financial results driven by the cabozantinib franchise, while navigating competitive and ...
Xcel Energy Inc. (NASDAQ: XEL) today reported 2025 second quarter GAAP earnings of $444 million, or $0.75 per share, compared with $302 million, or $0.54 per share in the same period in 2024. Second ...